Intraoperative Radiation Therapy Key Players and Product Evolution

Meet the Innovators in Intraoperative Radiation Therapy Market

What is Intraoperative Radiation Therapy?

The intraoperative radiation therapy market is experiencing significant growth due to increasing demand for targeted, time-efficient cancer treatments, and technological advancements in surgical oncology. IORT is a procedure that delivers a concentrated dose of radiation directly to the tumor during surgery, reducing exposure to surrounding healthy tissues. This method shortens post-operative radiation sessions, speeds up patient recovery, and improves local tumor control, making it an increasingly popular choice in modern cancer care around the world.

Market Growth

The global intraoperative radiation therapy market size is calculated at USD 69.6 million in 2025, grew to USD 74.09 million in 2026, and is projected to reach around USD 130.18 million by 2035. The market is expected to expand at a CAGR of 6.45% from 2026 to 2035.

Companies Outlook

• Major Investors: Leading investors in the market include prominent healthcare technology companies, venture capital firms, and hospital networks specializing in advanced oncology solutions. Key players such as Carl Zeiss Meditec AG, IntraOp Medical Inc., and Elekta AB are driving innovation through strategic funding, research collaborations, and global expansion efforts.
• Startup Ecosystem: The startup ecosystem in the market is growing rapidly, with new companies focusing on creating compact, affordable, and AI-powered IORT systems. These startups prioritize innovation in imaging accuracy, portability, and integration with surgical workflows. Partnerships with hospitals and research institutions are accelerating technology validation, clinical adoption, and expansion into global markets.

Top Giants in the Intraoperative Radiation Therapy Market

Carl Zeiss Meditec AG

Corporate Information

• Headquarters: Jena, Thuringia, Germany.
• Year Founded: 2002 (as Carl Zeiss Meditec AG).

Business Overview

Carl Zeiss Meditec AG is a leading medicaltechnology company that develops, manufactures, and markets diagnostic and therapeutic systems, with a strong focus on ophthalmology and microsurgery. Within its microsurgerybusiness scope, the company also offers intraoperative radiotherapy solutions (IORT) via its INTRABEAM® platform, enabling single-session radiation during surgery for oncology applications.

Business Segments / Divisions

The company’s revenue and operations are organized primarily into two strategic business units (SBUs):

• Ophthalmology (OPT): Solutions for diagnosis and treatment of eye diseases (intraocular lenses, lasers, diagnostics).
• Microsurgery (MCS): Visualization and surgical technology for neurosurgery, ENT, spinal, dental, and oncology workflows, including IORT systems.

Geographic Presence

Carl Zeiss Meditec has a global footprint. It operates in more than 50 countries, with production and R&D sites worldwide (including India and China) and major employee bases in the U.S., Japan, Spain, and France. Its distribution and service network spans Europe, the Americas, and AsiaPacific, enabling access to key oncology markets for IORT.

Key Offerings

INTRABEAM® 600 / INTRABEAM® 700: Compact intraoperative X-ray systems designed for IORT. INTRABEAM 700 features robotic-assisted precision, digital workflow architecture, and connectivity for intraoperative oncology applications (brain, breast, spinal) in surgery.

Applicators and treatmentplanning software: The system uses SMART Spherical Applicators, RFID-enabled workflow controls, and the Radiance™ planning simulation software to support intraoperative dose planning and execution.

SWOT Analysis

• Strengths:
  • Strong brand reputation and proven clinicaluse history with INTRABEAM, giving a competitive edge in the IORT market.
  • Global distribution and service network enabling penetration into developed and emerging oncology markets.
  • Integration of digital workflow, robotic assistance, and planning software adds value in the IORT environment.
• Weaknesses:
  • The IORT segment, while specialized, represents a smaller part of the company’s portfolio compared to ophthalmology; relative dependency on broader surgical/oncology cycles.
  • High-end systems come with significant cost and capitalinvestment implications, which may limit uptake in lower-resourced markets.
• Opportunities:
  • Growing demand for intraoperative radiotherapy (IORT) in breast, brain, and other solid tumors, especially with single-session approaches and rising oncology incidence.
  • Increasing shift toward ambulatory surgical centers, singlefraction treatment models, and IORT adoption in emerging markets that are expanding oncology infrastructure.
  • Further digitalization and workflow integration (robotics + connectivity + software) can create upsell opportunities and servicerecurring revenue streams.
• Threats:
  • Competition from other IORT device manufacturers (mobile electron LINACs, brachytherapy systems) that may offer alternative approaches.
  • Reimbursement, regulatory, and cost-effectiveness challenges across different countries that could slow the adoption of IORT equipment.
  • Macro-economic headwinds, healthcare budget constraints, and capital purchase delays in certain regions could affect sales cycles.

Recent News

In April 2025, Carl Zeiss Meditec AG obtained U.S. FDA approval for its INTRABEAM 700 platform, a next-generation IORT system for low-energy X-ray delivery during surgery.

iCAD, Inc.

Corporate Information

• Headquarters: Nashua, New Hampshire, U.S.
• Year Founded: 1984 (originally as Howtek, Inc., later renamed to iCAD, Inc. in 2002).

Business Overview

iCAD is a medicaltechnology company specializing in advanced cancer detection and treatment solutions. It operates primarily in two major business areas: detection (computer-aided detection/AI for imaging) and therapy (radiation therapy systems). In the IORT space, iCAD provides systems that enable intraoperative radiation delivery during surgery, most notably its Xoft® Axxent® Electronic Brachytherapy (eBx®) System, which delivers single-session radiation treatment directly in the operating room.

Business Segments / Divisions

• Detection Segment: Includes AIpowered image analysis, workflows, mammography CAD, density assessment, CT/MR imaging support, and related software/algorithms.
• Therapy Segment: Consists of the Xoft® eBx® System (electronic brachytherapy) and IORT solutions, enabling radiation treatment during surgery for breast, gynecological, skin, brain, and other tumors.

Geographic Presence

iCAD has a global presence: its detection and therapy solutions are used in over 50 countries. It has manufacturing and R&D facilities in New Hampshire, U.S., and operations in San Jose, California, U.S. It also maintains an office in Lyon, France, to support its European business.

Key Offerings

• Xoft® Axxent® eBx® System: A compact, isotope-free X-ray source designed for intraoperative radiation therapy (IORT). This system enables a complete course of radiation in a single session during surgery, reducing the need for multiple postoperative external beam treatments.
• The Xoft system is cleared for early-stage breast cancer, non-melanoma skin cancer, gynecological cancers, and is being expanded (via clinical trials) into brain, rectal, and head & neck tumors.
• The company additionally offers AI-powered detection suites (ProFound®) for cancer screening and diagnosis, which complements its therapy offerings by supporting early detection and workflow integration.

SWOT Analysis

• Strengths:
  • Unique IORT offering (Xoft system) that enables single-session intraoperative radiation therapy, which provides a competitive differentiator.
  • Strong global footprint in detection and therapy, with a history of FDA and CE clearances, allowing access to developed markets.
  • Presence in both detection and therapy segments gives iCAD strategic breadth across the cancercare continuum (screening to treatment).
• Weaknesses:
  • Relatively small company scale compared to major medicaldevice firms, which may limit resource availability for large-scale commercialization and global rollout in the IORT market.
  • The IORT technology (especially the therapy segment) may face longer adoption curves due to capital costs, infrastructure requirements, and hospital workflow integration.
• Opportunities:
  • Growth in demand for IORT technologies globally (breast, brain, head & neck, gynecological cancers) as surgical oncology shifts toward singlesession treatments and minimally disruptive workflows.
  • Expansion in emerging markets where IORT adoption is still nascent, offering first-mover advantages for companies with established technology.
  • Synergies between detection and therapy business lines: early diagnosis (via AI), increasing the pool of eligible patients who could benefit from intraoperative radiation solutions.
• Threats:
  • Competing technologies (mobile electron LINAC systems, traditional external beam radiotherapy, other intraoperative devices) may erode market share or slow adoption of iCAD’s IORT systems.
  • Reimbursement and regulatory hurdles in various geographies may delay adoption of intraoperative radiation therapies despite clinical advantages.
  • Capital expenditure constraints in hospitals (especially in less developed markets) may slow uptake of IORT systems requiring surgicalsuite integration.

Value Chain Analysis

Research and Development (R&D)

The R&D stage forms the core of the IORT value chain. It involves technological innovation in radiation delivery systems, miniaturized accelerators, and applicator design. Major medical device manufacturers, research institutes, and universities such as Varian Medical Systems, IntraOp Medical, and Zeiss Group focus on improving dose accuracy and real-time imaging integration. Partnerships between hospitals and academic institutions support prototype testing, AI-assisted treatment planning, and development of next-generation devices.

Clinical Trials and Approvals

After R&D, clinical validation confirms efficacy and safety. Clinical trials are usually conducted with oncology centers and regulatory authorities such as the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and the Ministry of Health, Labour and Welfare (MHLW) in Japan. These trials assess radiation dose accuracy, recurrence rates, and side effects. After successful trials, regulatory submissions, quality audits, and certification processes (ISO 13485, CE Mark) ensure compliance and allow market entry.

Patient Support and Service

This stage emphasizes post-implementation efficiency and patient satisfaction. Healthcare providers, oncology hospitals, and equipment suppliers collaboratively manage training programs, installation, and maintenance services. Patient support includes education on treatment outcomes, post-surgical monitoring, and managing side effects. Organizations like the American Cancer Society (ACS), the National Comprehensive Cancer Network (NCCN), and local oncology associations play crucial roles in raising awareness, providing guidance, and improving access to IORT technologies, ensuring optimal clinical and emotional support for patients.

Recent Developments

• In September 2025, GE HealthCare announced a new version of its software solution called Intelligent Radiation Therapy (iRT) for managing radiation therapy workflows. The update aims to reduce the time from diagnosis to treatment for patients. AI supports the iRT solution through GE. Third-party applications and healthcare integrations, along with the latest features, provide better links to systems most frequently used by radiation oncology departments and use information to enhance the department's effectiveness.
• In September 2025, Accuray Incorporated announced that the Accuray Stellar Solution represents the next step in the company's tradition of leading in adaptive radiation. The new Accuray technology is a solution, not just a system, for the U.S. market. It features a wide array of tools that enable clinical teams to meet the evolving treatment needs of patients receiving radiation therapy.
• In October 2024, Aster DM Healthcare, one of the largest integrated healthcare companies in India, made history by becoming the first hospital in the country to use Intra-Operative Electron Radiation Therapy (IOeRT). This groundbreaking move sets a new standard for cancer treatment. In a pioneering step that establishes a new benchmark in cancer care, Aster DM Healthcare has become the first healthcare facility in India to implement IOeRT, marking a significant shift in cancer treatment.

Exclusive Analysis

The global intraoperative radiation therapy market is experiencing a paradigm shift driven by the convergence of precision oncology, rising cancer incidence, and the increasing emphasis on value-based care models. The demand for single-session, intraoperative radiation interventions is accelerating as hospitals and surgical centers seek to optimize patient throughput, reduce postoperative complications, and shorten overall treatment timelines. Advanced electron-based and low-energy X-ray systems are enabling greater procedural efficiency while simultaneously mitigating exposure risks to healthy tissue, positioning IORT as a strategic solution within modern oncologic treatment protocols.

Geographically, North America maintains a dominant market position due to its mature healthcare infrastructure, high adoption of technologically advanced radiation devices, and robust reimbursement frameworks. However, Asia-Pacific represents the fastest-growing region, driven by increasing surgical oncology volumes, growing public awareness of cancer management options, and government investments in healthcare infrastructure and radiotherapy expansion. Emerging markets in Latin America, the Middle East, and Africa present substantial white-space opportunities for device manufacturers, particularly through strategic partnerships with hospitals and expansion into ambulatory surgical centers where conventional radiotherapy capacity remains limited.

From an investment and commercialization perspective, the IORT market offers attractive growth potential across multiple vectors. Key opportunities lie in the development of compact, cost-efficient systems tailored for mid-sized hospitals, integrated imaging and radiation platforms, and service-oriented business models including software, consumables, and workflow analytics. As clinical evidence continues to validate the efficacy of IORT in breast, brain, and head & neck cancers, the market is poised for accelerated adoption, creating favorable conditions for both incumbent players and new entrants seeking to capitalize on a rapidly evolving, high-margin niche within the broader radiation oncology ecosystem.

Partner with our experts to explore the Intraoperative Radiation Therapy Market at sales@towardshealthcare.com